FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue

References

• Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145(6):1215‐1229.
   PubMed Web of Science ®Google Scholar
• Waseem D, Tushar P. Intrahepatic, perihilar and distal cholangiocarcinoma: management and outcomes. Ann Hepatol. 2017;16(1):133–139.
   PubMed Web of Science ®Google Scholar
• Forner A, Vidili G, Rengo M, et al. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):98–107.
   PubMed Web of Science ®Google Scholar
• Brandi G, Rizzo A, Dall’Olio FG, et al. Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience. Int J Hyperthermia. 2020;37(1):479–485.
   PubMed Web of Science ®Google Scholar
• Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168–2179.
   PubMed Web of Science ®Google Scholar
• Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261–280.
   PubMed Web of Science ®Google Scholar
• Weinberg BA, Xiu J, Lindberg MR, et al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncol. 2019;10(4):652–662.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Combination therapy of dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer. Hepatobiliary Pancreat Dis Int. 2020;S1499-3872(20): 30248–4.
   Google Scholar
• Schweitzer N, Fischer M, Kirstein MM, et al. Risk estimation for biliary tract cancer: development and validation of a prognostic score. Liver Int. 2017;37(12):1852–1860.
   PubMed Web of Science ®Google Scholar
• DeOliveira ML, Cunningham SC, Cameron JL, et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg. 2007;245(5):755–762.
   PubMed Web of Science ®Google Scholar
• Saha SK, Zhu AX, Fuchs CS, et al. Forty-year trends in cholangiocarcinoma incidence in the US: intrahepatic disease on the rise. Oncologist. 2016;21(5):594–599.
   PubMed Web of Science ®Google Scholar
• Kelley RK, Bridgewater J, Gores GJ, et al. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):353–363.
   PubMed Web of Science ®Google Scholar
• Rizvi S, Gores GJ. Emerging molecular therapeutic targets for cholangiocarcinoma. J Hepatol. 2017;67(3):632–644.
   PubMed Web of Science ®Google Scholar
• Sharma A, Sharma KL, Gupta A, et al. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update. World J Gastroenterol. 2017;23(22):3978–3998.
   PubMed Web of Science ®Google Scholar
• Van Dyke AL, Shiels MS, Jones GS, et al. Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013. Cancer. 2019;125(9):1489–1498.
   PubMed Web of Science ®Google Scholar
• Marcano-Bonilla L, Mohamed EA, Mounajjed T, et al. Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations. Chin Clin Oncol. 2016 Oct;5(5):61. PMID: 27829275.
   PubMed Web of Science ®Google Scholar
• Matsukuma S, Tokumitsu Y, Shindo Y, et al. Essential updates to the surgical treatment of biliary tract cancer. Ann Gastroenterol Surg. 2019;3(4):378–389.
   PubMed Web of Science ®Google Scholar
• Kasumova GG, Tabatabaie O, Najarian RM, et al. Surgical management of gallbladder cancer: simple versus extended cholecystectomy and the role of adjuvant therapy. Ann Surg. 2017;266(4):625–631.
   PubMed Web of Science ®Google Scholar
• Primrose JN, Fox RP, Palmer DH, et al., Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5): 663–673.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Brandi G. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. Expert Rev Gastroenterol Hepatol. 2020;1–3. 10.1080/17474124.2021.1864325
   PubMed Web of Science ®Google Scholar
• Shroff RT, Kennedy EB, Bachini M, et al., Adjuvant therapy for resected biliary tract cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(12): 1015–1027.
   PubMed Web of Science ®Google Scholar
• Sanoyan DA, McNamara MG, Lamarca A, et al. Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives. Curr Opin Oncol. 2020;32(4):364–369.
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al., ABC-02 trial investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14): 1273–1281.
   PubMed Web of Science ®Google Scholar
• Javle M, Zhao H, Abou-Alfa GK. Systemic therapy for gallbladder cancer. Chin Clin Oncol. 2019;8(4):44.
   PubMed Web of Science ®Google Scholar
• Valle JW, Furuse J, Jitlal M, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25(2):391–398.
   PubMed Web of Science ®Google Scholar
• Lamarca A, Palmer DH, Wasan HS, et al., ABC-06 | a randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced/metastatic biliary tract cancers (ABC) previously-tr. J Clin Oncol. 2019;37(15_suppl): 4003-4003. 10.1200/JCO.2019.37.15_suppl.4003
   PubMed Web of Science ®Google Scholar
• Tella SH, Kommalapati A, Borad MJ, et al. Second-line therapies in advanced biliary tract cancers. Lancet Oncol. 2020;21(1):e29–e41.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Tober N, et al. Second-line treatment in advanced biliary tract cancer: today and tomorrow. Anticancer Res. 2020;40(6):3013–3030.
   PubMed Web of Science ®Google Scholar
• Valle JW, Lamarca A, Goyal L, et al. New horizons for precision medicine in biliary tract cancers. Cancer Discov. 2017;7(9):943–962.
   PubMed Web of Science ®Google Scholar
• Ricci AD, Rizzo A, Brandi G. The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box? ESMO Open. 2020;5(5):e001042.
   PubMed Web of Science ®Google Scholar
• Massa A, Varamo C, Vita F, et al. Evolution of the experimental models of cholangiocarcinoma. Cancers (Basel). 2020;12(8):2308.
   Web of Science ®Google Scholar
• Mizrahi JD, Shroff RT. New treatment options for advanced biliary tract cancer. Curr Treat Options Oncol. 2020;21(8):63.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol. 2021;8:1–10.
   Google Scholar
• Sipra QUAR, Shroff R. The impact of molecular profiling on cholangiocarcinoma clinical trials and experimental drugs. Expert Opin Investig Drugs. 2020;1–4. 10.1080/13543784.2021.1849139
   PubMed Web of Science ®Google Scholar
• Lamarca A, Barriuso J, McNamara MG, et al. Molecular targeted therapies: ready for “prime time” in biliary tract cancer. J Hepatol. 2020;73(1):170–185.
   PubMed Web of Science ®Google Scholar
• Malenica I, Donadon M, Lleo A. Molecular and immunological characterization of biliary tract cancers: a paradigm shift towards a personalized medicine. Cancers (Basel). 2020;12(8):2190.
   Web of Science ®Google Scholar
• Ricci AD, Rizzo A, Brandi G. Immunotherapy in biliary tract cancer: worthy of a second look. Cancer Control. 2020;27(3):1073274820948047.
   Web of Science ®Google Scholar
• Saborowski A, Lehmann U, Vogel A. FGFR inhibitors in cholangiocarcinoma: what’s now and what’s next? Ther Adv Med Oncol. 2020;12:1758835920953293.
   Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. Expert Opin Investig Drugs. 2020;1–8. DOI: 10.1080/13543784.2021.1837774. Epub ahead of print. PMID: 33054456.
   Web of Science ®Google Scholar
• Hoy SM. Pemigatinib: first approval. Drugs. 2020;80(9):923–929.
   PubMed Web of Science ®Google Scholar
• Chun YS, Javle M. Systemic and adjuvant therapies for intrahepatic cholangiocarcinoma. Cancer Control. 2017;24(3):1073274817729241.
   Web of Science ®Google Scholar
• Mahipal A, Kommalapati A, Tella SH, et al. Novel targeted treatment options for advanced cholangiocarcinoma. Expert Opin Investig Drugs. 2018;27(9):709–720.
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Tavolari S, et al. Circulating tumor DNA in biliary tract cancer: current evidence and future perspectives. Cancer Genomics Proteomics. 2020;17(5):441–452.
   PubMed Web of Science ®Google Scholar
• Touat M, Ileana E, Postel-Vinay S, et al. Targeting FGFR signaling in cancer. Clin Cancer Res. 2015;21(12):2684–2694.
   PubMed Web of Science ®Google Scholar
• Presta M, Chiodelli P, Giacomini A, et al. Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. Pharmacol Ther. 2017;179:171–187.
   PubMed Web of Science ®Google Scholar
• Helsten T, Elkin S, Arthur E, et al. The FGFR landscape in cancer: analysis of 4,853 tumors by next‐generation sequencing. Clin Cancer Res. 2016;22(1):259‐ 267.
   PubMed Web of Science ®Google Scholar
• Hallinan N, Finn S, Cuffe S, et al. Targeting the fibroblast growth factor receptor family in cancer. Cancer Treat Rev. 2016;46:51–62.
   PubMed Web of Science ®Google Scholar
• Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017;17(5):318–332.
   PubMed Web of Science ®Google Scholar
• Goyal L, Kongpetch S, Crolley VE, et al. Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat Rev. 2021 Feb 26;95:102170.
   PubMed Web of Science ®Google Scholar
• Rizvi S, Borad MJ. The rise of the FGFR inhibitor in advanced biliary cancer: the next cover of time magazine? J Gastrointest Oncol. 2016;7(5):789–796.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–1010.
   PubMed Web of Science ®Google Scholar
• Athauda A, Fong C, Lau DK, et al. Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation. Cancer Treat Rev. 2020;86:101998.
   PubMed Web of Science ®Google Scholar
• Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59(4):1427–1434.
   PubMed Web of Science ®Google Scholar
• Javle M, Bekaii-Saab T, Jain A, et al. Biliary cancer: utility of next-generation sequencing for clinical management. Cancer. 2016;122(24):3838–3847.
   PubMed Web of Science ®Google Scholar
• Wu YM, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3(6):636–647.
   PubMed Web of Science ®Google Scholar
• Morizane C, Ueno M, Ikeda M, et al. New developments in systemic therapy for advanced biliary tract cancer. Jpn J Clin Oncol. 2018;48(8):703–711.
   PubMed Web of Science ®Google Scholar
• Mahipal A, Tella SH, Kommalapati A, et al. FGFR2 genomic aberrations: achilles heel in the management of advanced cholangiocarcinoma. Cancer Treat Rev. 2019;78:1–7.
   PubMed Web of Science ®Google Scholar
• Chakrabarti S, Kamgar M, Mahipal A. Targeted therapies in advanced biliary tract cancer: an evolving paradigm. Cancers (Basel). 2020;12(8):2039.
   PubMed Web of Science ®Google Scholar
• Ueno M, Ikeda M, Sasaki T, et al. Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results. BMC Cancer. 2020;20(1):1105.
   PubMed Web of Science ®Google Scholar
• Plummer R, Madi A, Jeffels M, et al. A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;71(1):93–101.
   PubMed Web of Science ®Google Scholar
• Shroff RT, Yarchoan M, O’Connor A, et al. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. Br J Cancer. 2017;116(11):1402–1407.
   PubMed Web of Science ®Google Scholar
• Fostea RM, Fontana E, Torga G, et al. Recent progress in the systemic treatment of advanced/metastatic cholangiocarcinoma. Cancers (Basel). 2020;12(9):2599.
   PubMed Web of Science ®Google Scholar
• Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36(3):276–282.
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, El-Rayes BF, Droz Dit Busset M, et al. Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma. Br J Cancer. 2019;120(2):165–171.
   PubMed Web of Science ®Google Scholar
• Cleary James M, Gopa I, Do-Youn O, et al. Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion. J Clin Oncol. 2020;38(15_suppl):3603.
   Web of Science ®Google Scholar
• Oh PJ, Yin-Hsun F, Yen-Yang C, et al. Updated results of a phase IIa study to evaluate the clinical efficacy and safety of erdafitinib in Asian advanced cholangiocarcinoma (CCA) patients with FGFR alterations. J Clin Oncol. 2019;37(15_suppl):4117.
   Web of Science ®Google Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al., Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5): 671–684.
   PubMed Web of Science ®Google Scholar
• Merz V, Zecchetto C, Melisi D. Pemigatinib, a potent inhibitor of FGFRs for the treatment of cholangiocarcinoma. Future Oncol. 2020;17(4):389–402.
   PubMed Web of Science ®Google Scholar
• Goyal L, Meric-Bernstam F, Hollebecque A, et al. FOENIX-CCA2: a phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements. J Clin Oncol. 2020;38(15_suppl): 108-108. 10.1200/JCO.2020.38.15_suppl.108
   Web of Science ®Google Scholar
• Goyal L, Shi L, Liu LY, et al. TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma. Cancer Discov. 2019;9(8):1064–1079.
   PubMed Web of Science ®Google Scholar
• Goyal L, Saha SK, Liu LY, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 2017;7(3):252–263.
   PubMed Web of Science ®Google Scholar
• Smyth EC, Babina IS, Turner NC. Gatekeeper mutations and intratumoral heterogeneity in FGFR2-translocated cholangiocarcinoma. Cancer Discov. 2017;7(3):248–249.
   PubMed Web of Science ®Google Scholar
• Macias RIR, Banales JM, Sangro B, et al. The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis. 2018;1864(4 Pt B):1468–1477.
   PubMed Web of Science ®Google Scholar
• Palakurthi S, Kuraguchi M, Zacharek SJ, et al. The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity. Cancer Immunol Res. 2019;7(9):1457–1471.
   PubMed Web of Science ®Google Scholar
• Le Saux O, Falandry C, Gan HK, et al. Inclusion of elderly patients in oncology clinical trials. Ann Oncol. 2016;27(9):1799–1804.
   PubMed Web of Science ®Google Scholar
• Denson AC, Mahipal A. Participation of the elderly population in clinical trials: barriers and solutions. Cancer Control. 2014 Jul;21(3):209–214. PMID: 24955704.
   PubMed Web of Science ®Google Scholar
• Tai WM, Lim C, Ahmad A, et al. Do elderly patients benefit from enrollment into phase I trials? J Geriatr Oncol. 2015;6(3):241–248.
   PubMed Web of Science ®Google Scholar
• Mahipal A, Denson AC, Djulbegovic B, et al. Effect of age on clinical outcomes in phase 1 trial participants. Cancer Control. 2015 Apr;22(2):235–241. PMID: 26068771.
   PubMed Web of Science ®Google Scholar
• Cheng KK, Lim EY, Kanesvaran R. Quality of life of elderly patients with solid tumours undergoing adjuvant cancer therapy: a systematic review. BMJ Open. 2018;8(1):e018101.
   PubMed Web of Science ®Google Scholar
• Weiss J, Stinchcombe TE. Treatment of elderly patients with stage IV non-small-cell lung cancer. Expert Rev Anticancer Ther. 2012;12(1):111–120.
   PubMed Web of Science ®Google Scholar
• Montroni I, Ugolini G, Saur NM, et al. Personalized management of elderly patients with rectal cancer: expert recommendations of the European society of surgical oncology, European Society of Coloproctology, International Society of Geriatric Oncology, and American College of Surgeons commission on cancer. Eur J Surg Oncol. 2018;44(11):1685–1702.
   PubMed Web of Science ®Google Scholar
• Kanesvaran R, Mohile S, Soto-perez-de-celis E, et al. The globalization of geriatric oncology: from data to practice. Am Soc Clin Oncol Educ Book. 2020;40:1–9.
   PubMedGoogle Scholar
• Fallahzadeh R, Rokni SA, Ghasemzadeh H, et al. Digital health for geriatric oncology. JCO Clin Cancer Inform. 2018;2(2):1–12.
   PubMed Web of Science ®Google Scholar
• Nosaki K, Saka H, Hosomi Y, et al. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. Lung Cancer. 2019;135:188–195.
   PubMed Web of Science ®Google Scholar
• Cho E, Cho HA, Jun CH, et al. A review of hepatocellular carcinoma in elderly patients focused on management and outcomes. Vivo. 2019;33(5):1411–1420.
   PubMed Web of Science ®Google Scholar
• Prieske K, Trillsch F, Oskay-Özcelik G, et al. Participation of elderly gynecological cancer patients in clinical trials. Arch Gynecol Obstet. 2018;298(4):797–804.
   PubMed Web of Science ®Google Scholar
• Sedrak MS, Mohile SG, Sun V, et al. Barriers to clinical trial enrollment of older adults with cancer: a qualitative study of the perceptions of community and academic oncologists. J Geriatr Oncol. 2020;11(2):327–334.
   PubMed Web of Science ®Google Scholar
• Gregersen TA, Birkelund R, Wolderslund M, et al. What matters in clinical trial decision-making: a systematic review of interviews exploring cancer patients’ experiences. Scand J Caring Sci. 2019;33(2):266–278.
   PubMed Web of Science ®Google Scholar
• Tariq NU, McNamara MG, Valle JW. Biliary tract cancers: current knowledge, clinical candidates and future challenges. Cancer Manag Res. 2019;11:2623–2642.
   PubMed Web of Science ®Google Scholar
• Taghizadeh H, Müllauer L, Mader R, et al. Applied precision cancer medicine in metastatic biliary tract cancer. Hepatol Int. 2020;14(2):288–295.
   PubMed Web of Science ®Google Scholar
• Mahipal A, Tella SH, Kommalapati A, et al. Prevention and treatment of FGFR inhibitor-associated toxicities. Crit Rev Oncol Hematol. 2020 Nov;155:103091. Epub 2020 Sep 1. PMID: 32961472.
   PubMed Web of Science ®Google Scholar